Showing results (391-400 of 408) with videos related to
Sort By:
Pageof 41
Blood|October 19, 2022
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AMLMohamed L Sorror, Ted A Gooley, Barry E Storer, et al.Leukemia|November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGuillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.Blood|August 5, 2021
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemiaMohamed L Sorror, Barry E Storer, Amir T Fathi, et al.Journal of the National Comprehensive Cancer Network : JNCCN|January 24, 2014
Senior adult oncology, version 2.2014: clinical practice guidelines in oncologyArti Hurria, Tanya Wildes, Sarah L Blair, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2016
NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016Noam VanderWalde, Reshma Jagsi, Efrat Dotan, et al.Leukemia|March 3, 2021
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trialRichard A Larson, Sumithra J Mandrekar, Lucas J Huebner, et al.JCO Oncology Practice|February 13, 2020
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJohn M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.Blood|August 2, 2019
Genomic landscape of neutrophilic leukemias of ambiguous diagnosisHaijiao Zhang, Beth Wilmot, Daniel Bottomly, et al.Blood Advances|October 13, 2020
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trialMaria Teresa Voso, Richard A Larson, Dan Jones, et al.Blood|December 12, 2019
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemiaKonstanze Döhner, Christian Thiede, Nikolaus Jahn, et al.Pageof 41